TH-302: Phase I/II data

Interim data from 4 evaluable patients in the dose-escalation Phase I part of the U.S. Phase I/II TH-CR-403 trial showed that 240 mg/m 2 weekly IV TH-302 in combination with doxorubicin produced 2 par...